Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy

Yue Huang; Houli Zhao; Mi Shao; Linghui Zhou; Xiaoqing Li; Guoqing Wei; Wenjun Wu; Jiazhen Cui; Alex H Chang; Tao Sun; Yongxian Hu; He Huang

doi:10.1038/s41409-022-01699-2

Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy

Bone Marrow Transplant. 2022 Aug;57(8):1350-1353. doi: 10.1038/s41409-022-01699-2. Epub 2022 Jun 1.

Authors

Yue Huang^#^{1

2

3

4}, Houli Zhao^#^{1

2

3

4}, Mi Shao^#^{1

2

3

4}, Linghui Zhou^{1

2

3

4}, Xiaoqing Li^{1

2

3

4}, Guoqing Wei^{1

2

3

4}, Wenjun Wu^{1

2

3

4}, Jiazhen Cui^{1

2

3

4}, Alex H Chang⁵, Tao Sun^{6

7}, Yongxian Hu^{8

9

10

11}, He Huang^{12

13

14

15}

Affiliations

¹ Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China.
³ Institute of Hematology, Zhejiang University, Hangzhou, China.
⁴ Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China.
⁵ Shanghai YaKe Biotechnology Ltd, Shanghai, China.
⁶ Hangzhou ImmuQuad Biotech, LLC., Hangzhou, China. taosun@immuquad.com.
⁷ Institute of Wenzhou, Zhejiang University, Wenzhou, China. taosun@immuquad.com.
⁸ Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. 1313016@zju.edu.cn.
⁹ Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. 1313016@zju.edu.cn.
¹⁰ Institute of Hematology, Zhejiang University, Hangzhou, China. 1313016@zju.edu.cn.
¹¹ Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. 1313016@zju.edu.cn.
¹² Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. huanghe@zju.edu.cn.
¹³ Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China. huanghe@zju.edu.cn.
¹⁴ Institute of Hematology, Zhejiang University, Hangzhou, China. huanghe@zju.edu.cn.
¹⁵ Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China. huanghe@zju.edu.cn.

^# Contributed equally.

PMID: 35650329
DOI: 10.1038/s41409-022-01699-2

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cell- and Tissue-Based Therapy
High-Throughput Nucleotide Sequencing
Humans
Immunotherapy, Adoptive
Neoplasm, Residual
Receptors, Chimeric Antigen*

Substances

Receptors, Chimeric Antigen

Associated data

ChiCTR/ChiCTR1800018468